Advertisement

Topics

Cerus Company Profile

23:12 EST 13th December 2018 | BioPortfolio

At Cerus Corporation we have developed a platform technology (Helinx®) that prevents nucleic acid (DNA and RNA) replication. The Company's initial application of this technology is the development of the INTERCEPT Blood Systems to inactivate viruses, bacteria and other pathogens in the blood components used for transfusion - platelets, plasma and red blood cells.

Location

2411 Stanwell Drive
Concord
CA
94520
United States of America

Contact

Phone: (925) 288-6000
Fax: (925) 288-6001
Email: customer_services@cerus.com


News Articles [33 Associated News Articles listed on BioPortfolio]

Cerus to Present at the 2018 Stephens NY Investment Conference

Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin Green, Cerus’ vice president, finance ...

Cerus to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, will present and provide a corporate update at th...

Cerus to Present at the Baird 2018 Global Healthcare Conference

Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer, will present and provide a corporate update at ...

Cerus Endovascular Expands Intellectual Property Portfolio

FREMONT, Calif. and OXFORD, England, Nov. 27, 2018 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held medical device company engaged in the design and development Read more...

Cerus to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Vivek Jayaraman, Cerus’ chief commercial off...

Cerus secures FDA breakthrough device status for pathogen-reduced cryoprecipitate

The basis of the designation is improved treatment of massive hemorrhage, a life-threatening medical condition. Cerus chief scientific officer Laurence Corash said: “The proposed label indication fo...

Cerus enrolls first patients in Contour neurovascular system study

The CERUS (Contour Neurovascular System European Pre-Market Unruptured Aneurysm Study) study is designed to assess the safety of the company’s Contour neurovascular system, which is designed to ...

Cerus to Host Institutional Investor Meeting

Cerus Corporation (Nasdaq: CERS) today announced that it will host an Institutional Investor Meeting on Tuesday, October 16, 2018 in Boston, Massachusetts. The pro...

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Synthesis, antibacterial activity, synergistic effect, cytotoxicity, docking and molecular dynamics of benzimidazole analogues.

A series of 2-Cl-benzimidazole derivatives was synthesized and assessed for antibacterial activity. Antibacterial results indicated that compounds 2d, 2e, 3a, 3b, 3c, 4d and 4e showed promising activi...

Molecular modeling, synthesis, antibacterial and cytotoxicity evaluation of sulfonamide derivatives of benzimidazole, indazole, benzothiazole and thiazole.

A new series of heterocyclic molecules bearing sulfonamide linkage has been synthesized and screened for antibacterial activity. During antibacterial screening using broath dilution method, molecules ...

Synthesis, docking, ADMET prediction, cytotoxicity and antimicrobial activity of oxathiadiazole derivatives.

A series of molecules bearing oxathiadiazole, a five membered heterocyclic ring has been designed, synthesized and screened for antimicrobial activity. Molecules, 1a, 1b, 1d, 3a-b and 4a-b were found ...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Contour Neurovascular System - European Pre-Market Unruptured Aneurysm

Cerus Endovascular is sponsoring a prospective, multi-center trial to document the safety and performance of the Contour Neurovascular System™ ("Contour"). The purpose of the study is t...

Companies [3 Associated Companies listed on BioPortfolio]

Cerus

At Cerus Corporation we have developed a platform technology (Helinx®) that prevents nucleic acid (DNA and RNA) replication. The Company's initial application of this technology is the development o...

Cerus Corporation and SunCoast Blood Bank

Cerus Corporation

Condensed Consolidated Unaudited Balance Sheets

More Information about "Cerus" on BioPortfolio

We have published hundreds of Cerus news stories on BioPortfolio along with dozens of Cerus Clinical Trials and PubMed Articles about Cerus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cerus Companies in our database. You can also find out about relevant Cerus Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Corporate Database Quicklinks



Searches Linking to this Company Record